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Abstract 
Background 
Antibiotic treatment recommendations based on susceptibility data from routinely 
submitted urine samples may be biased because of variation in sampling, laboratory 
procedures, and inclusion of repeat samples, leading to uncertainty about empirical 
treatment.   
 
Aim 
To describe and compare susceptibilities of E. coli cultured from routinely submitted 
samples, with E. coli causing UTI from a cohort of systematically sampled, acutely 
unwell children.  
 
Design, setting and participants 
Susceptibilities of 1458 E. coli isolates submitted during the course of routine primary 
care for children <5 years (routine care samples), compared to susceptibilities of 79 E. 
coli isolates causing UTI from 5107 children <5years presenting to primary care with 
an acute illness (systematic sampling: the DUTY cohort).  
 
Results  
The percentage of E. coli sensitive to antibiotics cultured from routinely submitted 
samples were; amoxicillin 45.1% (95% CI 42.5% to 47.7%); co-amoxiclav using the 
lower systemic breakpoint (BP) 86.6%  (84.7% to 88.3%); cephalexin  95.1% (93.9% 
to 96.1%); trimethoprim 74.0% (71.7% to 76.2%); and nitrofurantoin 98.2% (97.4% 
to 98.8%)..  
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The percentage of E. coli sensitive to antibiotics cultured from systematically sampled 
DUTY urines considered to be positive for UTI were; amoxicillin 50.6% (39.8% to 
61.4%);  co-amoxiclav using the systemic BP 83.5% (73.9 to 90.1%); co-amoxiclav 
using the urinary BP 94.9% (87.7% to 98.4%); cephalexin 98.7% (93.2% to 99.8%); ; 
trimethoprim 70.9% (60.1% to 80.0%);  nitrofurantoin 100% (95.3% to 100.0%); and  
ciprofloxacin 96.2% (89.4 to 98.7%).. 
 
Conclusion  
 E. coli susceptibilities from routine and systematically obtained samples were 
similar. Most UTIs in preschool children remain susceptible to nitrofurantoin, co-
amoxiclav, and cephalexin.  
 
 
Key words: Urinary Tract Infections; Pediatrics; Diagnosis; Anti-Bacterial Agents; 
antibiotic resistance; surveillance; treatment recommendations 
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Introduction 
Early, effective antibiotic treatment of UTI in young children alleviates acute 
symptoms, and may also limit long-term sequelae.(1) Antibiotics should ideally be 
prescribed only to those who have a UTI, using an antibiotic with the narrowest 
effective spectrum. Empirical treatment is more or less universal in primary care, 
given that urine culture results take several days, and as yet there are no rapid point of 
care tests that give a sufficiently robust indication of aetiology and the susceptibility 
of infecting organisms. 
 
Guidelines generally recommend that choice of empiric antibiotics for suspected 
urinary tract infection (UTI) in acutely unwell children should depend on local 
susceptibilities.(1, 2) Such information is usually derived from routinely collected 
data, and may provide biased estimates because of variation in sampling decisions by 
individual clinicians, differing laboratory procedures and the inclusion of repeat 
samples in databases. The susceptibilities of organisms from urines submitted in 
routine care and in organisms causing UTI from systematically obtained urines in 
primary care have not been directly compared. 
 
Information about susceptibilities of cultured organisms in urine samples routinely 
submitted from children in primary care may therefore not be generalizable to the 
child presenting with acute illness in primary care who has not had recurrent UTIs, 
who is not known to have a structural renal tract abnormality, or who has complex 
medical needs. Previous studies have generally focused on epidemiological studies of 
asymptomatic children(3-6) or on children presenting to health care with symptoms 
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clearly attributable to UTI.(7) A recent study from the US found that the resistance 
patterns differed between routinely submitted outpatient and inpatient urine 
samples.(8) We know of only one large study that has focused on culture results in 
systematically sampled acutely unwell children, and we know of no study that has 
analysed systematically sampled urine from acutely unwell children in a central 
research laboratory using more intensive techniques that are currently undertaken in 
routine laboratory practice.(9) Susceptibilities of organisms cultured in systematically 
sampled children in the community with an acute illness (not just those suspected of 
UTI) have not been compared to sensitivities in urines submitted for routine 
laboratory culture (which usually includes only those children with a high suspicion 
of UTI, recurrent UTI and with renal tract abnormalities). Systematic sampling 
involves taking a urine sample form all eligible children rather than sampling based 
only clinical suspicion. Such a comparison would help determine the applicability of 
findings surveillance based on routinely submitted samples to children presenting in 
primary care with an acute illness.  
 
We therefore set out to compare the susceptibilities of E. coli in samples positive for 
UTI in routinely submitted samples from children in the community and compare 
these to those cultured from systematically obtained samples considered positive for 
UTI in acutely unwell pre-school children presenting to primary care.  
 
Methods 
 
Samples submitted during the course of routine care 
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Antimicrobial susceptibility data for urines submitted to microbiology laboratories 
across Wales in 2011 was extracted from DataStore, a data repository that extracts all 
results from the laboratory information management systems into a common 
searchable format. DataStore was searched for all urines submitted from general 
practice from children in the first five years of life with an E. coli UTI (identified 
directly using UTI Chromogenic agar) that had susceptibility testing performed from 
any of the 10 laboratories in Wales. Culture and susceptibilities were performed using 
common standard operating procedures, based on the National Standard Method 
(BSOP 41).(10) Susceptibilities were performed by BSAC disc diffusion tests.(12) 
The data do not differentiate between mid-stream, clean-catch, nappy pad or catheter 
urines. Data from duplicate isolates were removed prior to analysis. Organisms from 
the same patient, with the same identification and susceptibility pattern isolated ≤ 91 
days from the date of the initial isolate were excluded. To reduce the effect of variable 
susceptibility testing rates to different antibiotics, individual hospital or laboratory 
sensitivities are only presented for organisms where ≥80% of such isolates from the 
given sample type was tested and where the number of isolates tested exceeds 10. In 
the case of first generation cephalosporins, eight laboratories reported cephalexin and 
two laboratories cefradine. For the purposes of this analysis the results have been 
combined and reported as cephalexin.  For co-amoxiclav a systemic breakpoint (BP) 
was used for interpretation. We were not able to obtain culture results for urine 
submitted UK wide.  
 
Samples from children undergoing systematic urine sampling (The DUTY Cohort) 
The Diagnosis of Urinary Tract infection in Young children (DUTY) study was a 
multicentre, prospective, diagnostic cohort study that recruited children aged under 
 
 
8 
five years, between April 2010 to April 2012.(11) Multi-centre ethical approval was 
granted by the South West Southmead Research Ethics Committee (previously 
Southmead Research Ethics Committee, then South West 4 REC), Ref #09/H0102/64. 
 
DUTY Cohort Participants 
Children presenting unwell to primary care with an acute illness episode of up to 28 
days duration, even where the responsible clinician was confident of the diagnosis 
(e.g. a child with bronchiolitis), or with urinary symptoms, were eligible to take part 
in the study. The sample therefore included all children with an acute illness, not just 
those at high risk of UTI. Children were excluded if: they were neither 
constitutionally unwell (e.g. acute conjunctivitis only) or an absence of urinary 
symptoms; they were known to have a neurogenic or surgically reconstructed bladder; 
they were using a permanent or intermittent urinary catheter; the main presenting 
problem was trauma; or antibiotics had been taken within seven days. 
 
DUTY cohort procedure 
Urine samples were obtained by clean catch, where possible, for children who were 
toilet trained or for whom the parent or DUTY Study Research Nurse was happy to 
attempt collection. For children still using nappies (diapers) whose parents did not 
think clean catch would be successful, Newcastle Nappy Pads were used. Nappy pads 
were inserted into the nappy (diaper) then removed as soon as the child urinated to 
reduce the risk of contamination. Once the child had urinated the nappy pad was 
removed and the urine was extracted with a syringe into a sterile container. 
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If it was not possible to obtain a sample before the child left the primary care site, the 
parent was given the necessary equipment and advice on taking the sample at home. 
They were given a labelled Sterilin™ bottle into which to transfer the urine, and 
asked to write the time and date the sample was obtained. They were advised to store 
the sample in the refrigerator and return it to the primary care site (directly or via 
collection by the DUTY Study Research Nurse/Clinical Studies Officer) as soon as 
possible, preferably within 24 hours.  
 
DUTY cohort laboratory analysis 
Urine samples were split into two fractions. Since results might be needed for clinical 
management, the priority fraction was sent to the local NHS laboratory routinely used 
by the recruiting primary care site for routine diagnostic processing. If sufficient urine 
was available, the second fraction was sent to the Specialist Antimicrobial 
Chemotherapy Unit, Public Health Wales Microbiology Laboratory, Cardiff (Central 
Research Laboratory). A minimum of 1ml volume was required for analysis. Urine 
samples were transported to the central laboratory in a urine monovette containing 
boric acid (Sarstedt) using standard biological sample post office SafeboxesTM. In the 
central research laboratory, microscopy was performed using an IQ200 automated 
urine analyser (Iris Diagnostics Ltd, UK) to determine counts of white blood cells, red 
blood cells, squamous epithelial cells, bacteria and other artefacts. Quantitative total 
and species-specific counts were recorded for all organisms present. Disc 
susceptibilities were performed on any organism present at >103 cfu/mL according to 
BSAC guidelines.(12) Antimicrobials tested for all isolates were trimethoprim, 
nitrofurantoin and amoxicillin. Gram negative and positive isolates were further tested 
with co-amoxiclav, cephalexin, ciprofloxacin, cefpodoxime and cefoxitin, 
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vancomycin, novobiocin respectively.  Oral doses of co-amoxiclav are in 2:1 ratio 
amoxicillin/clavulanate. Susceptibility testing is performed according to standardized 
methods; the British Society for Antimicrobial Chemotherapy (BSAC) standardized 
method uses 2:1 ratio and the European Committee for Antimicrobial Susceptibility 
Testing (EUCAST) standardized method uses a 2mg/L fixed concentration of 
clavulanate. The BSAC method was the most used method in the UK whilst the 
EUCAST method is the method due to be adopted by UK labs in the future. In this 
study, we used both discs to cover any differences that may be highlighted.  
 
Urinary breakpoints are employed when the UTI is uncomplicated, as in most adult 
community patients. Systemic breakpoints are used when the UTI may be more 
complicated (i.e. causing a systemic infection). In the DUTY children we thought it 
advisable to interpret using both breakpoints to cover the possibility that a system 
infection could be present.   
 
The definition of UTI in the Central Research Laboratory was ≥105 CFU/mL of a 
pure or predominant uropathogen (where predominant was defined as a 3 log10 
difference in growth between the predominant and next organism). For the purposes 
of the DUTY study, an uropathogen is defined as any Enterobacteriaceae. We used 
the cut point of ≥105 CFU/mL to reduce risk of including false positives. 
 
Results 
Samples submitted during the course of routine care 
In the routine database analysis, we identified 1458 urine samples for children in the 
first five years of life in 2011 that were submitted from general practices in the course 
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of routine care, which grew E. coli and were tested for antimicrobial susceptibility 
(only 1343 were tested against amoxicillin). We do not have data for the total number 
of samples that were submitted for children in this age group, only those growing E. 
coli on culture. 45.1% (95% CI 42.5% to 47.7%) were susceptible to amoxicillin, 
86.6% (84.7% to 88.3%) to co-amoxiclav, 95.1% (93.9% to 96.1%) to cephalexin, 
74.0% (71.7% to 76.2%) to trimethoprim, and 98.2% (97.4% to 98.8%) to 
nitrofurantoin. 
 
Systematically sampled dataset (DUTY cohort) 
A total of 6390 urine samples were obtained from the 7163 recruited children. The 
majority of samples (73.5%) were successfully split into two fractions and were sent 
to both the local NHS and central research laboratories, but there was insufficient 
urine for a fraction to be sent to the Central Research Laboratory in 1073 (15.0%) of 
cases and 64.2% had arrived by two days, 80.4% by 3 days, and 91.1 by 4 days. 
 
5231 (73.0%) samples were received at the Central Research Laboratory, 124 could 
not be processed (e.g. the sample leaked in transit or there was insufficient urine), and 
5107 (71.3%) were cultured and had a ‘UTI status’ result. 94 of these sample culture 
results were considered to indicate a UTI according to the definition of UTI we used, 
giving a prevalence of 1.8%. 
 
Table 1 provides demographic features of the 5107 children from the DUTY cohort 
who had samples cultured in the research laboratory. 19.7% (n=1006) were between 1 
and 2 years old, with 8.1% (n=412) less than 6 months old. There were equal numbers 
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of males and females (49.1% vs. 50.9% respectively). Most were ethnically ‘white’ 
(82.9%, n=4235).  
 
Table 2 shows the comparative susceptibility of E. coli considered the causative agent 
for UTI isolated from community urines from across Wales in 2011, in patients aged 
0-5 years inclusive (n=1458) and from urines obtained by systematically sampling 
children presenting to primary care with an acute illness (the DUTY study samples).  
 
The online supplementary table provides details of sensitivities to all 
Enterobacteriaceae (n=94) including the E. coli (n=79) cultured from urines samples 
of acutely unwell children (DUTY Cohort) in the first five years of life considered 
positive for UTI.  
 
 
Discussion 
Urine sampling rates from primary care are variable and may be biased towards 
recurrent and more severe cases, and so antibiotic susceptibilities from routinely 
submitted samples may not be representative of organisms causing urinary tract 
infection (UTI) in children presenting with acute illness in the course of routine care, 
and this may bias treatment recommendations that are based on routinely submitted 
samples. We found that the antimicrobial susceptibilities of organisms considered to 
be causing a UTI cultured in routinely submitted samples was remarkably similar to 
susceptibilities of organisms considered to be causing a UTI cultured from urine in 
systematically sampled children under the age of five. Most UTIs in preschool 
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children remain susceptible to nitrofurantoin, co-amoxiclav (using the urinary BP in 
uncomplicated UTI), and cephalexin.  
 
Our systematically sampled data set was obtained from the largest prospective study 
of UTI in children presenting to primary care with acute illness. We recruited large 
numbers and had over 5000 centrally analysed urine results. All of these urine 
samples were processed according to the same standard operating procedures, and 
cultured using sensitive methods. 
 
For the analysis presented in this paper, we based our definition of a 
microbiologically diagnosed UTI on culture results and did not include clinical factors 
in this definition. Our UTI prevalence (1.8%) was lower than found in previous 
studies.(13)  Our definition included only significant growths of Enterobacteriaceae 
UTI, which may have missed some UTI caused by non-Enterobacteriaceae.  Urine 
samples were often difficult to obtain and the nappy pad method was commonly used 
in the younger children, and this may be associated with greater levels of 
contamination and increased risk of false negative and false positive results. Some 
urine volumes were insufficient to be split to allow for Research Laboratory analysis, 
which may have resulted in risk of selection bias. We did not use methods such as 
suprapubic aspiration or catheterisation, as these are not feasible for large numbers of 
children in primary care. Urine samples were transported to the Central Research 
Laboratory by post and most had arrived in the lab by 2 days after the sample was 
taken. 
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Heginbothom and colleagues found no evidence that screening and duplicate samples 
materially affected estimates of levels of resistance in routinely submitted samples for 
all age groups.(14) We are not aware of any study that has compared the culture 
results of systematically sampled urines from acutely unwell children who are found 
to have laboratory proven UTI with data derived from samples submitted during the 
course of routine care. 
 
NICE guidelines for managing children under 3 months and those with suspected 
upper urinary tract infection state "consider referral and treat with 7 to 10 days of oral 
antibiotic such as co-amoxiclav or cephalosporin (IV if oral not possible)". For older 
children and those with lower UTI, NICE recommends treating with oral antibiotics 
for 3 days, and that “the choice of antibiotics should be directed by locally developed 
multidisciplinary guidance. Trimethoprim, nitrofurantoin, cephalosporin or 
amoxicillin may be suitable.”(1) High rates of resistance to amoxicillin should be 
borne in mind when making decisions about empiric therapy.  The American 
Academy of Pediatrics clinical practice guideline for the diagnosis and management 
of the initial UTI in febrile infants and children 2 to 24 months states that the usual 
choices for oral treatment of UTIs include a cephalosporin, amoxicillin plus 
clavulanic acid, or trimethoprim- sulfamethoxazole, but recommend against 
nitrofurantoin because serum and parenchymal antimicrobial concentrations may be 
insufficient to treat pyelonephritis or urosepsis.(15) Adverse effects include anorexia, 
nausea, vomiting, and diarrhoea, and acute and chronic pulmonary reactions have 
been reported.(16) Nitrofurantoin should not be used when pyelonephritis is suspected 
 
We do not have clinical details for the children in the routinely submitted dataset, and 
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so are not able to make detailed comparisons between these children and the children 
in the DUTY cohort.  The children who had their urine sampled during the course of 
routine care have had urine sampled based on clinical suspicion of a UTI, whereas the 
basis for sampling in the DUTY cohort was systematic, in that we asked clinicians to 
submit a sample on all sequential eligible children.   Despite this difference in 
approach to identifying children for sampling in the two dataset, we found that most 
organisms in routinely submitted samples positive for UTI from children in the first 
five years of life and from those samples positive from systematically sampled 
acutely unwell children aged from three months until five years in primary care 
produced remarkably similar results.  
 
This suggests that estimates of antimicrobial susceptibilities derived from surveillance 
using routinely submitted samples from young children are applicable to empirical 
treatment decision for acutely unwell children in primary care. 
 
Resistance to trimethoprim in E. coli from both systematically sampled urines and 
routine care urines was between 26% and 29%. This is equivalent to the proportion 
trimethoprim resistance in E. coli from a UK multicentre study (26.7%) in 2003. (21)  
However trimethoprim resistance levels may vary depending on locality; a report 
published for the London area reported trimethoprim resistance 40% for E. coli.(20) It 
is difficult to know what level is too high to continue to recommend trimethoprim as a 
first line empirical therapy as  there is not always a clear correlation between a 
resistant UTI organism and a treatment failure.(17) This is thought to be partly due to 
high concentrations of antimicrobial agents which can be reached in the urine.(17) It 
has been estimated that a resistance proportion of 30% would still be associated with 
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an 85% clinical success rate.(17) Co-amoxiclav and cephalexin are broader spectrum 
alternatives, albeit at the increased risk of generating subsequent antimicrobial 
resistance. These results also support the recommendation to use nitrofurantoin. (10) 
This agent does not reach therapeutic concentrations in the blood or other tissues so is 
less likely to drive resistance in commensal organisms or be effective in 
pyelonephritis.(18) Increases in resistance to nitrofurantoin are less marked than to 
other commonly used antimicrobials.(19) However, when renal involvement or sepsis 
is suspected, in younger children or in children with known renal impairment, an 
alternative should be used.(1, 16) 
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Table 1: Demographic features of 5017 children presenting to primary care with 
an acute illness and enrolled in the DUTY study between April 2010 and April 
2012 for whom a urine sample was analysed by the research laboratory1 
 
 n % 
Age 
Less than 6 months 412 8.1 
6 months to less than 12 months 675 13.2 
1 year to less than 2 years 1006 19.7 
2 years to less than 3 years 989 19.4 
3 years to less than 4 years 1138 22.3 
4 years plus 887 17.4 
   
Gender 
Male 2507 49.1 
Female 2600 50.9 
    
Ethnic groupings 
White 4235 82.9 
Mixed 261 5.1 
Asian 203 4.0 
Black 325 6.4 
Other 33 0.6 
Missing 50 1.0 
   
1. No similar data available for the routinely collected samples 
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Table 2: Comparison of susceptibilities for E. coli considered the causative agent of UTI 
from samples collected as part of routine care (Wales 2011) and part of a systematic urine 
sampling (DUTY cohort). 
 
Wales 2011 (n=1458) DUTY (n=79) 
% Susceptible 95% CI % Susceptible 95% CI 
Co-amoxiclav 86.6 
84.7 to 
88.3 
189.9 81.3 to 94.8 
2100.0 95.3 to 100.0 
383.5 73.9 to 90.1 
494.9 87.7 to 98.4 
Amoxicillin 45.1 
42.5 to 
47.7 
50.6 39.8 to 61.4 
Cephalexin 95.1 
93.9 to 
96.1 
98.7 93.2 to 99.8 
Nitrofurantoin 98.2 
97.4 to 
98.8 
100.0 95.3 to 100.0 
Trimethoprim 74.0 
71.7 to 
76.2 
70.9 60.1 to 80.0 
Ciprofloxacin N/A N/A 96.2 89.4 to 98.7 
12:1 ratio with systemic breakpoint of S≤8 mg/L 
22:1 ratio with urinary breakpoint of S≤32 mg/L 
3fixed 2mg/L with systemic breakpoint of S≤8 mg/L 
4 fixed 2mg/L with urinary breakpoint of S≤32 mg/L 
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